Entopsis has licensed cutting-edge research tools from its new PCRopsis™ product line for the Chinese market to Beijing Wan Bridge Intelligent Technology. Backed by patent pending technologies, PCRopsis™’s three cost- and time-saving solutions for sample processing are expected to usher in a new direction for laboratory R&D.
Miami, Florida, July 9, 2018: Leading biotech R&D company Entopsis has recently licensed three state-of-the-art PCRopsis™ technologies aimed at the lucrative Chinese life sciences market. Launched a few months ago in the United States, PCRopsis™ is Entopsis’ new product line focused on providing cost- and time-saving solutions for clinical and research labs. PCRopsis™ was created to greatly simplify sample processing steps, reduce cost and address bottlenecks in lab automation processes, while delivering test-ready samples of high quality.
“We are excited to exclusively license our latest PCRopsis™ technologies. This deal validates our team’s commitment to providing efficient and effective biotech solutions on a global scale,” stated Dr. Obdulio Piloto, Entopsis CEO and co-founder. Entopsis’ CFO Dr. George Huang elaborated that “Entopsis will be receiving a minimum of $2.8M in revenue over three years with expected revenue projections of more than $6.25M in this period.”
All PCRopsis™ products are meant to address key problems and improve efficiency in laboratory research & development with their unique capabilities. Each of them is USA manufactured in a certified ISO13485/ISO9001 facility to ensure compliance with the highest quality standards. The following three PCRopsis™ products are licensed exclusively for the Chinese market.
PCRopsis™ Cell is a revolutionary tool which allows for direct PCR from cellular samples without DNA isolation or centrifugation, in under 20 minutes, making it fast and easily automatable. Further, the PCRopsis™ Cell kit can process diverse and mixed cellular samples containing bacteria, mammalian cells and fungi, offering breadth and scope unmatched by competitors.
PCRopsis™ Blood Cell Separator is engineered to separate white blood cells, or specific cell types, from red blood cells starting with whole blood. This unique cell separation approach does not require density media, magnets, centrifugation or specialized equipment. PCRopsis™ Blood Cell Separator is expected to disrupt lab automation by providing a one-step automation-friendly alternative to the currently labor-intensive Ficoll®-Paque protocol.
PCRopsis™ Concentrator offers a simple, quick and hands-free means of concentrating samples. The first of its kind, the tool concentrates DNA, proteins and cells within five minutes without the need for any equipment. PCRopsis™ Concentrator impacts numerous areas of research where concentration of analytes is critical to assay sensitivity. Such areas include clinical diagnostics, proteomics, metabolomics, and microbiomics.
Entopsis is the only Florida-based start-up supported by the Thiel Foundation’s Breakout Labs, which backs ground-breaking companies developing deep science technologies. Entopsis is best known for OpsisDx®, its diagnostic platform which distinguishes multiple medical conditions from a single urine sample without the need for analyzing DNA, RNA or circulating tumor cells. The OpsisDx® platform is currently being tested in clinical studies.